Antibiotic resistance in Gramnegative. The BIG THREE.Ab, Pa, and Kp!

Size: px
Start display at page:

Download "Antibiotic resistance in Gramnegative. The BIG THREE.Ab, Pa, and Kp!"

Transcription

1 Antibiotic resistance in Gramnegative bacteria: The BIG THREE.Ab, Pa, and Kp! Robert A. Bonomo, MD Chief, Medical Service Director VISN 10 GRECC Louis Stokes Cleveland VAMC Vice Chairman, Department of Medicine University Hospitals Case Medical Center Professor, Case Western Reserve University School of Medicine Objectives Overview of the problem of ATB R in Gram negative bacteria A. baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Summarize the rapidly expanding landscape of resistance determinants Use this knowledge to devise effective treatment strategies 1

2 Part I MDR and PDR Ab The clinical challenge of A. baumannii Multi-Drug Resistant (MDR) A. baumannii are among the most problematic pathogens encountered by clinicians 2

3 A. baumannii - a prime example of a mismatch between unmet medical need and the current antimicrobial research and development pipeline Why? Ab facts.. Most common drug resistant pathogen in the US and world 50-70% of Ab clinical isolates are now extensively drug resistant (XDR; i.e. resistant to all antibiotics except colistin or tigecycline), reflecting a >15- fold increase since Pan drug resistant; XDR strains of Ab increased from <4% in 2000 to >60-80% in

4 Does resistance matter? BSI by XDR Ab cause >50-60% mortality In a recent study 13,796 patients in 1,265 ICUs from 75 countries, Ab was one of only two of 19 microorganisms strongly linked (p<0.01) to increased mortality by multivariate analysis; Odds ratio for death-1.53 Factors? LPS, Fe siderophores, PLD, OMPs, biofilm?? McGowan ICHE 2019, Hoffman et al, ICHE 2010, McGowan AJM 2006 Paterson CID 2006, Perez AAC 2007, Vincent JAMA 2009, Gordon JAC housekeeping genes (total 2,976 nt) in 154 diverse A. baumannii strains A. baumannii is a genetically compact species 4

5 antimicrobial resistance is a major selective advantage that drives the ongoing rapid clonal expansion of these highly problematic agents of nosocomial Infections. 5

6 Threat 1. β-lactam mediated resistance In A. baumannii resistance to β-lactams presents one of the most significant challenges β-lactamases Efflux mediated elimination-adeabc Penicillin Binding Proteins (PBPs) Outer Membrane Proteins Alterations-5 Omps; β-lactamase Arsenal All representative classes (A-D) AmpC Cephalosporinase (ADC) background nearly 70 now! Emerging Importance of MβL (IMP, VIM, SIM, and NDM) and OXA-type carbapenemases IS elements with ADCs and OXAs; integrons Class A β-lactamases (ESBLs-PER, TEM); role? 6

7 AmpC (Acinetobacter Derived Cephalosporinases, 70 + ADCs) Differences in expression? TAZ R bla ADC FEP S IS Aba 1 Insertion sequences 1180 bp insert promoter Increased transcripts by RT PCR or increased protein expression Bou et al., 2000, AAC; Mammeri et al., 2003 AAC; Hujer et al., 2006 AAC; Bou et al., 2007 in resubmission Corvec et al., 2003, JACS; Hertier et al., CMI, 2005; Ruiz et al., FEMS, 2007; Babic et al., ICAAC 2007 OXA β-lactamases Naturally occurring and acquired Types and Groups Narrow spectrum Carbapenem hydrolyzing (CHDLs) ES type Carbapenemases (Acinetobacter) Are not ES; do not have both properties Imipenem> meropenem Poirel et al AAC

8 Global spread of OXA carbapenemases in Acinetobacter Outbreaks everywhere OXA-24/40* was also the first carbapenemhydrolyzing oxacillinase reported in Chicago (Quinn Lab-signal of emerging problem in US tertiary care centers). both plasmid and chromosomally located OXA-23,-40 and -58 at WRAMC from 2003 to 2005 (US* also UK* troops); outbreak on the West Coast US?? OXA-143 emerging? Lolans et al, AAC 2006; Hujer et al, AAC 2006; Poirel et al, 2010 bla OXA carbapenemases and IMI R? AdeABC IMI R bla oxa-23/40, others IS Aba Hertier et al., AAC 2005; Poirel et al., AAC

9 ENTER NDM-1!! Thanks Dr. Perez MβLs of Acinetobacter: IMP (22+) and VIM (24) type are major MβLs Others are also being found (SIM-Seoul imipenemase) Integron borne NDM-1, -2 now in Ab Molecular characterization of bla NDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007 J. Antimicrob. Chemother. (2011) 66(9): Pfeifer et al. 9

10 More than one variant? NDM-1 NDM-2 (29 H to A) NDM-3 NDM-4 (154 M to L) Threat 2. Colistin R Polymyxins (E and B) are cationic polypeptide atbs Colistin SO 4 for PO and Colistimethate Na + (sodium colistin methanesulphonate, colistin sulfomethate sodium) for IV Colistin displaces Ca +2 and Mg +2 from PO4-3 groups of membrane lipids; Insertion of polymyxins disrupts the OM and LPS is released ; anti-endotoxin activity ; rapidly bactericidal??? Urban et al. reported a case of polymyxin B R A. baumannii Falgas, et al, CID 2005; Urban 2001 AAC; Li et al AAC 2006; Li et al Int Journal of Antimicrobial Agents,

11 Colistin R Colistin R due to modifications of LPS; pmr (US) vs. lpxa,-c, and -D (Australian); Parks lab in S. Korea found the same locus Heteroresistance (subpopulations of genetically identical subclones that are more R than the parent ) by Li et al; implications for rx? Moffatt AAC 2010, Li et al AAC 2006 ; Hawley et al AAC 2007, Adams et al AAC 2009 Hawley et al. describe the phenomenon of colistin dependence. 77 yo diabetic male with FI and bacteremia; increasingly luxuriant growth Survey of Resistance genes in A. baumannii bla AMEs QRDR RND Efflux pumps OMPs Tet ADC aacc1 gyra AdeABC HMP-AB teta OXA aacc2 parc AdeM OmpA tetb IMP aacc3 AdeIJK kda tetm VIM, GIM SIM, SPM, NDM aaca4 AdeS CraS AdeDE 25/29 kda CarO PER apha1 Res Is?? OprD (43kDA) TEM* apha6 AbaR 1-10 OmpW tetx PBPs SHV aada1 Col R pmrab CTX-M rmt* 44, 47kDa, 22 integrons 11

12 The Resistance Island 86 Kb, 88 orfs, 82 orfs from another source and 45 resistance genes AbaR1-10! Fournier et al., PLoS Genet Jan;2(1):e7. Epub 2006 Jan 13. Part II MDR P. aerugoinosa The resistance challenge of the ages 12

13 Pa facts Colonization rates by Pa are high in the hospital (50%); immunity and burn Seriously ill patients in ICUs. Aggregate NNISS and EU data 20 to 30% of nosocomial pneumonias 10 to 20% of urinary tract infections 3% to 10% of bloodstream infections, Mechanisms of resistance 13

14 Pa and ATB R ß-lactamases-all classes represented Cephalosporinases, class A ESBLs (PER), OXA ESBLs (OXA-10, -14), Carbapenemases (KPC and GES), MβLs Loss of permeability Quinolones and aminoglycosides Active antimicrobial efflux Alterations in DNA gyrase Aminoglycoside-modifying enzymes 14

15 Antimicrobial resistance Efflux pumps MFS major facilitator superfamily ABC ATP-binding cassette family RND resistance nodulation division SMR small multidrug resistance MATE multidrug and toxic compound extrusion RND and MFS extrude antibiotics and work by proton motive force; In GNRs, RND works with MFP (periplasmic membrane fusion protein) and OEP (outer membrane efflux protein) to get thru both membranes Antimicrobial resistance MexAB-oprM operon Expressed constitutively in wild-type cells; cipro-r, B-lactam-R, TCN-R, macrolide-r, chloro-r, TMP-SMX-R System is also growth phase regulated, its expression increasing in late log phase Transports homoserine lactones (quorum sensing) mexr upstream controls 15

16 16

17 The mysteries of the biofilm.. Trends in Microbiology Jan 2001; 9(1): Part III MDR K. pneumoniae 17

18 Why should we be afraid of Klebsiella pneumoniae? KPCs and OXA-48! KPC K. pneumoniae AMIKACIN R AMPICILLIN R CEFAZOLIN R CEFTAZIDIME R CIPROFLOXACIN R TRIMETH/SULFA R MEROPENEM 4 ug/ml (> 64) GENTAMICIN S AMPICILLIN/SUL R CEFOTETAN R CEFEPIME R PIP/TAZO R 18

19 Status of the KPC global epidemic Two phenotypes; MIC< 8 and MIC> 32 ST258> ST384, ST388 Plasmids from ST258 has been transferred to E. coli in patients. Colistin resistant ST258 Novel testing methods (ChromAgar, Boronates, PCR/ESI-MS, Microarray methods/checkpoints Doi, CID, 2011; KPC attack 19

20 Worst case scenario!! Clinical issues ATB control?cephalosporin and β- Lactam-β Lactamase Inhibitor restriction policies? special populations? How best to implement IC? Carrot or stick? Detection? ESBL identification? Inoculum effect? Colistin-as empiric Rx??? combined with aminoglycosides (gent); rifampin 20

21 What is the impact of infections caused by KPC producing bacteria? Is there increased mortality?? The mortality in the IRE group was 33%, compared to 9% among controls. Being an IRE case was significantly associated with increased mortality (P 0.043) 21

22 Goal: identify risk factors associated with mortality among patients with carbapenemresistant K. pneumoniae infx. Results carbr K. pneumoniae infection was independently associated with recent organ or stem-cell transplantation (P =.008), receipt of mechanical ventilation (P =.04), longer LOS before infection (P =.01), ceph (P=.02) and carba (P <.001) exposure. Is there something different about this population of Kp? 22

23 Results Case patients were more likely than control patients to die during hospitalization (48% vs 20%; P <.001) die from infection (38% vs 12%; P <.001). Removal of the focus of infx (ie, debridement) was independently associated with patient survival (P=.002). The timely administration of antibiotics with in vitro activity against carbapenem-resistant K. pneumoniae was not associated with patient survival. OXA-48 The blaoxa-48 gene with insertion sequence IS1999 in K. pneumoniae. First described in 2004, Turkey, next Tunisia, France, Senegal, the Netherlands, Morocco, Spain, Ireland, Israel Germany; ST 395, carried the blaoxa-48 gene located onto a 62- kb conjugative plasmid 23

24 Options for treatment? The basis for a new research agenda in Infectious Diseases What can I use to treat MDR Ab, Pa, and Kp when isolates are resistant to all antibiotics? 24

25 Therapy for MDR Ab, Pa, Kp Colistin? Tigecycline? Minocycline? Rifampin? Teicoplanin? Vancomycin?? Do we have enough patients studied properly? Animal models may have (significant) limitations? Colistin is King 25

26 After an exhaustive review of much the available evidence. Perez et al, AAC 2007 Most recent reviews Lung infections Munoz-Price and Weinstein, NEJM

27 Colistin + rif? Colistin + minocycline? Not enough data Antagonistic? Synergy? Sometimes??? Meta-analysis (Falagas IJAA)--no statistical difference in cure rates when colistimethate sodium alone was compared with the combinations with meropenem, piperacillin/tazobactam or ampicillin/ sulbactam J of Infec)on, 2006, 53, 274 Need better controls; at least it doesn t hurt yet can it prevent hetero-resistance?? Nation et al, J of Infection 27

28 The colistin bottom line Efficacy rate of 57-76% in IV form; microbiological eradication of %Renal tox 0-37% Nebulized colistin (CF studies + others) effective; FDA warning; impact of shift to more resistant strains ; use with IV!! 32 cases microbiological eradication in the CNS with ITh/IVe colistin (safe e 1) (2.5 mg/kg, mg ITh) Colistin was independently associated with higher mortality vs. treatment with sulbactam in patients with A. binfections Colistin and vanco?? 28

29 Problems Control group?? retrospective design, Variable dosing and duration Other atbs No monitoring of resistance Nephrotoxicity,? which owing to the retrospective character of the studies cannot be attributed exclusively to colistin. Major concerns real? 1.Rapid resistance can emerge; 2.Cases of breakthrough bacteremia reported; 3. Adequacy of blood levels?? Pachon and Vila Curr Opin Investig Drugs Feb;10(2): Giamarellou & Poulakou, Drugs Michalopoulos A, Falagas ME. Expert Opin Pharmacother Apr;11(5): Tigecycline? Patients % Improvement % bacteremic patients treated with tige failed to clear their bacteremia 10-fold more commonly than patients treated with comparator drugs Gordon JAC 2009, Gardiner CID 29

30 Accumulating enough isolates Higgins, JAC 2010 My recommendations Susceptible strains 1. A/S, 3 q6 2. Imipenem; meropenem is worrisome; dori?? Cephalosporins are tricky. 3. Colistin loading dose 5 mg/kg not to exceed 300 mg then (4.5 mg/kg/day) and split it tid(1.5 mg/kg q8). 4. Colistin and rifampin, tigecycline, or minocycline) 30

31 If NDM-1 Treatment options Aztreonam +?? BAL30072, meropenem and?? Fosfomycin? Release of NXL104 with ceftazidime KPC Rx 68 blakpc-possessing K. pneumoniae including 23 tigecycline- and/or colistin-nonsusceptible strains. By agar dilution, 93% of the overall KpKPC were susceptible (MIC50/90 of 16/64 g/ml, respectively). Notably, 5 out of 6 extremely drug-resistant (tigecycline and colistin nonsusceptible) KpKPC were susceptible to fosfomycin. Compared to agar dilution, disk diffusion was more accurate than Etest. 31

32 The end? Very complex challenges ahead The prevailing wisdom is find new targets, but can we improve what we currently have? Consider the importance of genomics in helping us understand the changes we are seeing-not new drugs! Diagnostics-Broad range Summary Extraordinary challenge against cunning pathogens Basic understanding of molecular biology is needed (the complexities of resistance genes will only increase) Research is needed in therapeutics and infection control CALL TO ARMS: Coordinate scientific and clinical trials to answer these important questions 32

33 Acknowledgments Drs. Keith Kaye and George Alangaden and the organizers of the conference NIH, VA Merit Review; Cubist Chris Bethel, Steve Marshall, Magda Taracila, Kristine Hujer and Andrea Hujer Drs. Krisz Papp-Wallace, Marisa Winkler, Federico Perez, Curtis Donskey, Dror Marcham 33

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

Mechanism of antibiotic resistance

Mechanism of antibiotic resistance Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance

More information

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antimicrobial Resistance Acquisition of Foreign DNA

Antimicrobial Resistance Acquisition of Foreign DNA Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple

More information

Witchcraft for Gram negatives

Witchcraft for Gram negatives Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a

More information

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance

More information

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic

More information

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria

Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL

Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Acinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.

Acinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat

More information

WHY IS THIS IMPORTANT?

WHY IS THIS IMPORTANT? CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change

More information

Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections

Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester

Breaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships

More information

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,

More information

Acinetobacter baumannii: from S to PDR

Acinetobacter baumannii: from S to PDR Acinetobacter baumannii: from S to PDR P. Plésiat French National Reference Center for Antibiotic Resistance University Hospital Jean Minjoz 25030 Besançon, France No conflict of interest! IDSA CID 2009,

More information

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO) Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health

More information

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia

More information

MULTIDRUG-RESISTANT GRAM NEGATIVE NONFERMENTATIVE

MULTIDRUG-RESISTANT GRAM NEGATIVE NONFERMENTATIVE MULTIDRUG-RESISTANT GRAM NEGATIVE NONFERMENTATIVE BACTERIA Sanda Sardelić, MD, PhD CHC Split, Croatia ESCMID Course, Primošten, Croatia, September 28-30, 2011 MDR nonfermentative bacteria Opportunistic

More information

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD

More information

Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes

Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :

More information

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh

What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options

More information

Global Alliance for Infections in Surgery. Better understanding of the mechanisms of antibiotic resistance

Global Alliance for Infections in Surgery. Better understanding of the mechanisms of antibiotic resistance Better understanding of the mechanisms of antibiotic resistance Antibiotic prescribing practices in surgery Contents Mechanisms of antibiotic resistance 4 Antibiotic resistance in Enterobacteriaceae 9

More information

β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018

β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018 β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus

More information

EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS

EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS David J. Feola, Pharm.D., Ph.D. Assistant Professor University of Kentucky College of Pharmacy Disclosures Research Funding Pfizer Objectives

More information

Infectious Disease: Drug Resistance Pattern in New Mexico

Infectious Disease: Drug Resistance Pattern in New Mexico Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?

More information

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre

Prevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase

More information

W J C C. World Journal of Clinical Cases. Antimicrobial resistance in Acinetobacter baumannii : From bench to bedside. Abstract INTRODUCTION REVIEW

W J C C. World Journal of Clinical Cases. Antimicrobial resistance in Acinetobacter baumannii : From bench to bedside. Abstract INTRODUCTION REVIEW W J C C World Journal of Clinical Cases Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.12998/wjcc.v2.i12.787 World J Clin Cases 2014 December

More information

Antimicrobials & Resistance

Antimicrobials & Resistance Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran

The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran 1 2 The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran Sedigheh Rafiei Tabatabaei, MD, MPH Associate Professor of Pediatric Infectious Diseases

More information

Microbiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:

Microbiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR: Microbiology Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention June 2017 MeshHp (VS) Medical Care Center Dr. Eberhard & Partner Dortmund (ÜBAG) www.labmed.de MVZ Dr. Eberhard &

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

Antimicrobial Resistance Strains

Antimicrobial Resistance Strains Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Sepsis is the most common cause of death in

Sepsis is the most common cause of death in ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker

The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial

More information

DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014

DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014 DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,

More information

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Antibiotics & Resistance

Antibiotics & Resistance What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed

More information

Taiwan Surveillance of Antimicrobial Resistance (TSAR)

Taiwan Surveillance of Antimicrobial Resistance (TSAR) Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)

Detecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP) Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa

More information

Antibiotic resistance a mechanistic overview Neil Woodford

Antibiotic resistance a mechanistic overview Neil Woodford Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles

More information

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011 Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research

More information

1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS

1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO

More information

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How

More information

Antimicrobial Resistance: A Growing Concern for Healthcare Security and Resilience

Antimicrobial Resistance: A Growing Concern for Healthcare Security and Resilience Antimicrobial Resistance: A Growing Concern for Healthcare Security and Resilience Neil Woodford HPA AMRHAI - Colindale Resistance is entirely natural...and is ancient Permafrost samples Late Pleistocene

More information

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Resistant Gram-negative Bacteria

Resistant Gram-negative Bacteria Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria

More information

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013 Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases

More information

Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,

Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1

More information

10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide

10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide I have no conflicts of interest in relation to this program Whitney Jones, PharmD Antimicrobial Stewardship Pharmacist Vanderbilt University Medical Center October 25, 2012 Understand the epidemiology

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

OAHHS Webinar. Christopher D. Pfeiffer, MD, MHS April 30, 2014

OAHHS Webinar. Christopher D. Pfeiffer, MD, MHS April 30, 2014 OAHHS Webinar Christopher D. Pfeiffer, MD, MHS April 30, 2014 Learning Objectives / Outline 1. Understand: What are CRE? Which CRE are most important? Why? 2. Learn about CRE epidemiology, nationally and

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Infectious Disease Issues in the Intensive Care Unit

Infectious Disease Issues in the Intensive Care Unit Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

Antimicrobial Resistance and Prescribing

Antimicrobial Resistance and Prescribing Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks

More information

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

More information

The relevance of Gram-negative pathogens for public health situation in India

The relevance of Gram-negative pathogens for public health situation in India The relevance of Gram-negative pathogens for public health situation in India Dr. Sanjay Bhattacharya MD, DNB, DipRCPath, FRCPath, CCT (UK) Consultant Microbiologist Tata Medical Center www.tmckolkata.com

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA

More information

10/15/08. Activity of an Antibiotic. Affinity for target. Permeability properties (ability to get to the target)

10/15/08. Activity of an Antibiotic. Affinity for target. Permeability properties (ability to get to the target) Beta-lactam antibiotics Penicillins Target - Cell wall - interfere with cross linking Actively growing cells Bind to Penicillin Binding Proteins Enzymes involved in cell wall synthesis Activity of an Antibiotic

More information

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department

More information

A novel variant of the β-lactamase ADC-61 gene in multi-drug resistant Acinetobacter baumannii

A novel variant of the β-lactamase ADC-61 gene in multi-drug resistant Acinetobacter baumannii A novel variant of the β-lactamase ADC-61 gene in multi-drug resistant Acinetobacter baumannii Y. Zhou, S.-J. Teng, L. Yang, S.-B. Li and Y. Xu Clinical Laboratory Department, The Second People s Hospital

More information

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital

More information

Summary of unmet need guidance and statistical challenges

Summary of unmet need guidance and statistical challenges Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Breakthrough medicines targeting the growing global health threat of antibiotic resistance. Jefferies Healthcare Conference June 2017

Breakthrough medicines targeting the growing global health threat of antibiotic resistance. Jefferies Healthcare Conference June 2017 Breakthrough medicines targeting the growing global health threat of antibiotic resistance Jefferies Healthcare Conference June 2017 June 2017 Our Mission To build an enduring biopharmaceutical company

More information

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia

Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*

More information

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!

More information